CUR - Neuralstem, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.07
-0.05 (-4.46%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.12
Open1.12
Bid1.01 x 1100
Ask1.31 x 1800
Day's Range1.07 - 1.12
52 Week Range0.88 - 3.09
Volume73,695
Avg. Volume112,750
Market Cap16.221M
Beta0.75
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Should You Have Neuralstem Inc’s (NASDAQ:CUR) In Your Portfolio?
    Simply Wall St.5 days ago

    Should You Have Neuralstem Inc’s (NASDAQ:CUR) In Your Portfolio?

    If you own shares in Neuralstem Inc (NASDAQ:CUR) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure ofRead More...

  • Germantown biopharma Neuralstem appoints interim CEO
    American City Business Journals2 months ago

    Germantown biopharma Neuralstem appoints interim CEO

    Key story highlights: Germantown biopharmaceutical company Neuralstem Inc. named Jim Scully interim CEO. The board also appointed William Oldaker, a member of the board since 2007, as chairman. Maryland stem cell therapy company Neuralstem Inc. (NASDAQ: CUR) has named Jim Scully interim CEO.

  • Benzinga2 months ago

    Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 31) Allakos Inc (NASDAQ: ALLK ) (listed July 19 following its IPO) ...

  • Neuralstem, Inc. (CUR): Updated Phase II Trial Success in Major Depressive Disorder Takes the Street by Storm
    SmarterAnalyst10 months ago

    Neuralstem, Inc. (CUR): Updated Phase II Trial Success in Major Depressive Disorder Takes the Street by Storm

    Neuralstem (NASDAQ:CUR) stock is on fire after revealing a huge clinical win that has sent bulls storming the market today to buy into piece of the biotech action. Shares are rocketing 100% on back of the drug maker's successful updated Phase 2 clinical data in major depressive disorder, where the company's NSI-189 asset impressed at the 56th American College of Neuropsychopharmacology (ACNP) Annual meeting.

  • Does Neuralstem Inc’s (CUR) Past Performance Indicate A Stronger Future?
    Simply Wall St.10 months ago

    Does Neuralstem Inc’s (CUR) Past Performance Indicate A Stronger Future?

    Examining Neuralstem Inc’s (NASDAQ:CUR) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met or exceedRead More...

  • Associated Press10 months ago

    Neuralstem reports 3Q loss

    On a per-share basis, the Germantown, Maryland-based company said it had a loss of 18 cents. The biopharmaceutical company posted revenue of $2,500 in the period. Its adjusted revenue was $3,000. The company's ...

  • Capital Cube10 months ago

    ETFs with exposure to Neuralstem, Inc. : November 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Neuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
    Capital Cube10 months ago

    Neuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017

    Categories: Yahoo FinanceGet free summary analysis Neuralstem, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Neuralstem, Inc. – Cytokinetics, Incorporated, Geron Corporation, Acorda Therapeutics, Inc., Aceto Corporation, Intra-Cellular Therapies, Inc., Supernus Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc. (CYTK-US, GERN-US, ACOR-US, ACET-US, ITCI-US, SUPN-US and ... Read more (Read more...)

  • One Thing To Consider Before Buying Neuralstem Inc (CUR)
    Simply Wall St.11 months ago

    One Thing To Consider Before Buying Neuralstem Inc (CUR)

    For Neuralstem Inc’s (NASDAQ:CUR) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock in theRead More...